Instituto Grifols
As of the edition of 20 October 2026, Instituto Grifols runs 6 drugs, 5 of them marketed; it is on route A at 0 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 5 |
| Status not established | 1 |
| Total | 6 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Human immunoglobulin g | Ended 2015 (orphan exclusivity) | 0 |
| Albumin human | none listed | 0 |
| Fibrinogen, human | Ended 2021 (computed from the first US licence) | 0 |
| Fostamatinib | Ends 2031 (patent) | 3 |
| Thrombin | Ended 2019 (computed from the first US licence) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 1 target.
| Target | Route |
|---|---|
| SYK Tyrosine-protein kinase SYK | Route B |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Instituto Grifols needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Eye: 1 trials led
- Immune system: 1 trials led